pyrazines has been researched along with Encephalopathy, Toxic in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Danduga, RCSR; Dondapati, SR; Grace, L; Kanakaraju, VK; Kola, PK; Tadigiri, RVB | 1 |
| Beric, A; Hochster, H; Ivy, P; Joseph, SO; Kobrinsky, B; Liebes, L; Malankar, A; Muggia, F | 1 |
| Avan, A; Cavaletti, G; Ceresa, C; Geldof, AA; Giovannetti, E; Peters, GJ | 1 |
| Alé, A; Bruna, J; Monbaliu, J; Morell, M; Navarro, X; Udina, E; van de Velde, H | 1 |
| Argyriou, AA; Bruna, J; Cavaletti, G; Kalofonos, HP; Kyritsis, AP | 1 |
| Cavaletti, G; Gilardini, A; Marmiroli, P | 1 |
| Cammarota, S; Cavaletti, G; Frigeni, B; Jann, S; Lanzani, F; Mattavelli, L; Petrò, D; Rossini, F | 1 |
| Avezza, F; Canta, A; Carozzi, VA; Cavaletti, G; Ceresa, C; Chiorazzi, A; Crippa, L; Gilardini, A; Marmiroli, P; Meregalli, C; Oggioni, N | 1 |
| Schiff, D; van den Bent, MJ; Wen, PY | 1 |
| Alexandrescu, DT; Dasanu, CA | 1 |
| Cheng, B; Cheung, YK; Lee, SM | 1 |
| Alé, A; Bruna, J; Jaramillo, J; Navarro, X; Udina, E; Velasco, R | 1 |
| Chaudhry, V; Umapathi, T | 1 |
| Devereux, S; Gupta, S; Mufti, GJ; Pagliuca, A; Schey, S | 1 |
| Cavaletti, G; Nobile-Orazio, E | 1 |
4 review(s) available for pyrazines and Encephalopathy, Toxic
| Article | Year |
|---|---|
Bortezomib-induced peripheral neurotoxicity: an update.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Incidence; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Proteasome Inhibitors; Pyrazines; Risk Factors; Severity of Illness Index | 2014 |
Proteasome inhibition: a promising strategy for treating cancer, but what about neurotoxicity?
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Demyelinating Diseases; Humans; Myelin Sheath; Neoplasms; Neurotoxicity Syndromes; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines | 2008 |
Neurological adverse effects caused by cytotoxic and targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Bevacizumab; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dacarbazine; Drug Approval; Epothilones; Humans; Imatinib Mesylate; Indoles; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Piperazines; Pyrazines; Pyrimidines; Pyrroles; Sunitinib; Temozolomide; Tubulin Modulators; United States; United States Food and Drug Administration | 2009 |
Toxic neuropathy.
Topics: Animals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Epothilones; Genetic Therapy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoxazoles; Leflunomide; Neuritis; Neuroprotective Agents; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Pyrazines; Pyridoxine; Thalidomide | 2005 |
2 trial(s) available for pyrazines and Encephalopathy, Toxic
| Article | Year |
|---|---|
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Dose-Response Relationship, Drug; Drug Monitoring; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neoplasms; Neurotoxicity Syndromes; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Proteasome Inhibitors; Pyrazines; Severity of Illness Index; Tumor Burden | 2013 |
Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Topics: Adult; Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Electrophysiology; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines | 2008 |
9 other study(ies) available for pyrazines and Encephalopathy, Toxic
| Article | Year |
|---|---|
Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington's disease-like symptoms in rats.
Topics: Animals; Behavior, Animal; Catalase; Corpus Striatum; Glutathione; Hippocampus; Huntington Disease; Lipid Peroxidation; Male; Maze Learning; Mitochondria; Motor Activity; Neuroprotection; Neuroprotective Agents; Neurotoxicity Syndromes; Nitro Compounds; Oxidative Stress; Propionates; Pyrazines; Rats; Rats, Wistar; Superoxide Dismutase | 2018 |
Characterization of and protection from neurotoxicity induced by oxaliplatin, bortezomib and epothilone-B.
Topics: Adrenal Gland Neoplasms; Amifostine; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cyclin B2; Epothilones; Microtubule-Associated Proteins; Neurites; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pheochromocytoma; Pyrazines; Radiation-Protective Agents; Rats; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Tumor Cells, Cultured | 2014 |
Treatment with anti-TNF alpha protects against the neuropathy induced by the proteasome inhibitor bortezomib in a mouse model.
Topics: Action Potentials; Animals; Antibodies; Boronic Acids; Bortezomib; Cells, Cultured; Cytokines; Disease Models, Animal; Female; Ganglia, Spinal; Gene Expression Regulation; Mice; Motor Activity; Neural Conduction; Neurotoxicity Syndromes; Pain Measurement; Pain Threshold; Proteasome Inhibitors; Pyrazines; Sciatic Nerve; Sensory Receptor Cells; Time Factors; Tumor Necrosis Factor-alpha | 2014 |
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats.
Topics: Animals; Antineoplastic Agents; Behavior, Animal; Blood Cell Count; Blood Chemical Analysis; Body Weight; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Hot Temperature; Neural Conduction; Neurotoxicity Syndromes; Pain; Pain Measurement; Peripheral Nervous System Diseases; Pyrazines; Rats; Rats, Wistar; Sciatic Nerve | 2010 |
Prophylactic antivirals may be helpful in prevention of varicella-zoster virus reactivation in myeloma, but are they safe?
Topics: Acyclovir; Antineoplastic Agents; Antiviral Agents; Boronic Acids; Bortezomib; Drug Monitoring; Herpes Zoster; Herpesvirus 3, Human; Humans; Incidence; Multiple Myeloma; Neurotoxicity Syndromes; Pyrazines; Renal Insufficiency; Virus Activation | 2010 |
Continual reassessment method with multiple toxicity constraints.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Calibration; Clinical Trials, Phase I as Topic; Computer Simulation; Cyclophosphamide; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Epidemiologic Research Design; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Models, Statistical; Neoplasms; Neurotoxicity Syndromes; Prednisolone; Probability; Pyrazines; Statistical Distributions; Thrombocytopenia; Vincristine | 2011 |
Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Disease Models, Animal; Female; Immunohistochemistry; Mice; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines; Risk Factors | 2011 |
Life-threatening motor neurotoxicity in association with bortezomib.
Topics: Aged; Boronic Acids; Bortezomib; Critical Illness; Female; Humans; Middle Aged; Multiple Myeloma; Neurotoxicity Syndromes; Peripheral Nervous System Diseases; Pyrazines | 2006 |
Bortezomib-induced peripheral neurotoxicity: still far from a painless gain.
Topics: Animals; Boronic Acids; Bortezomib; Humans; Neurotoxicity Syndromes; Pain; Pyrazines | 2007 |